Analyses of novel prognostic factors in neuroblastoma patients.

Neuroblastoma (NB) is the most common malignant solid tumor in childhood. There are well-recognized prognostic factors in NB such as age at diagnosis, organ of origin, stages, MYCN gene amplification, and expression of H-ras, trkA and survivin. Moreover, we investigated the expression of vascular endothelial growth factor (VEGF), tyrosine hydroxylase (TH), p53, stem cell factor (SCF) and c-kit of its receptor with quantitative real-time polymerase chain reaction (PCR) in 22 NBs and 4 other tumors (one malignant lymphoma, one malignant teratoma, and 2 rhabdomyosarcomas) samples. The correlation between patients' prognoses and the expression of TH or c-kit was newly recognized, particularly the good prognosis in patients in whom c-kit highly expressed and the poor prognosis contrarily associated with low or no expression, although the SCF of its ligand had no relationship with patient prognosis. It is possible that tumors without c-kit expression can not react with SCF (via the autocrine or paracrine system) and remain immature. It may be that this is a new critical clinical event in NB patients.

[1]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.

[2]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[3]  K. Møllgård,et al.  Stem cell factor and c-Kit in human primordial germ cells and fetal ovaries , 2005, Molecular and Cellular Endocrinology.

[4]  Rie Ito,et al.  Significance of survivin mRNA expression in prognosis of neuroblastoma. , 2005, Biological & pharmaceutical bulletin.

[5]  P. Span,et al.  Survivin is an independent prognostic marker for risk stratification of breast cancer patients. , 2004, Clinical chemistry.

[6]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[7]  Haidong Wang,et al.  The expression and significance of survivin mRNA in urinary bladder carcinomas , 2004, Journal of Cancer Research and Clinical Oncology.

[8]  R. Parwaresch,et al.  Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis , 2004, Oncogene.

[9]  D. Kobayashi,et al.  Survivin mRNA expression in patients with breast cancer. , 2002, Anticancer research.

[10]  T. Sugimoto,et al.  Prognostic discrimination among neuroblastomas according to ha‐ras/trk A gene expression , 1998, Cancer.

[11]  P. Haber,et al.  Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  H. Enomoto,et al.  Neuronal src and trk A protooncogene expression in neuroblastomas and patient prognosis , 1998, International journal of cancer.

[13]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[14]  G. Krystal,et al.  Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.

[15]  B. Quesnel,et al.  p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .

[16]  S. Kyo,et al.  Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. , 1994, Cancer research.

[17]  J. Pelletier,et al.  Absence of p53 gene mutations in primary neuroblastomas. , 1993, Cancer research.

[18]  C. Dominici,et al.  Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. , 1993, Cancer research.

[19]  A. Cantor,et al.  Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.

[20]  D. Stram,et al.  Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. , 1993, Journal of the National Cancer Institute.

[21]  K. Zsebo,et al.  Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. , 1992, Blood.

[22]  H. Shirasawa,et al.  Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. , 1991, Cancer research.

[23]  David A. Williams,et al.  Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.

[24]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[25]  J. Minna,et al.  p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.

[26]  T. Nagatsu.  The human tyrosine hydroxylase gene , 1989, Cellular and Molecular Neurobiology.

[27]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[28]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.

[29]  J. Mallet,et al.  A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics , 1987, Nature.

[30]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[31]  E. Frenkel,et al.  Characterization of human neuroblastoma cell lines established before and after therapy. , 1986, Journal of the National Cancer Institute.

[32]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[33]  T. Sawada,et al.  MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.

[34]  H. Varmus,et al.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.

[35]  A. Donfrancesco,et al.  Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  G. Brodeur.  Molecular basis for heterogeneity in human neuroblastomas. , 1995, European journal of cancer.